{"id":17180,"date":"2025-09-19T21:06:57","date_gmt":"2025-09-19T18:06:57","guid":{"rendered":"https:\/\/testsunucusu.com\/acibadem\/doctor\/elif-senocak-tasci\/"},"modified":"2025-12-10T21:26:11","modified_gmt":"2025-12-10T18:26:11","slug":"elif-senocak-tasci","status":"publish","type":"idel_doctor","link":"https:\/\/acibademinternational.com\/doctor\/elif-senocak-tasci\/","title":{"rendered":"Elif \u015eenocak Ta\u015f\u00e7\u0131"},"content":{"rendered":"<p><!-- Education & Experience --><\/p>\n<div class=\"info-education\">\n<p>Assoc. Prof. <strong>Elif \u015eenocak Ta\u015f\u00e7\u0131<\/strong> is a medical oncologist affiliated with Ac\u0131badem Health Group. She completed her medical oncology training at Ac\u0131badem Mehmet Ali Ayd\u0131nlar University Faculty of Medicine in 2023 and has continued her clinical and academic work within the Ac\u0131badem network since 2025. Known for a patient-centered approach, she combines evidence-based cancer care with clear communication and compassionate support for patients and families. Her interests include delivering personalized treatment plans, participating in multidisciplinary care, and staying current with advances in oncology to improve outcomes and quality of life for those she treats.<\/p>\n<div style=\"height: 20px;\"><\/div>\n<p><strong>Education<\/strong><\/p>\n<ul>\n<li><span class=\"doctorDate\">2023<\/span> <span class=\"doctorDescription\">Ac\u0131badem Mehmet Ali Ayd\u0131nlar University Faculty of Medicine Medical Oncology<\/span><\/li>\n<li><span class=\"doctorDate\">2017<\/span> <span class=\"doctorDescription\">Duzce University Faculty of Medicine Internal Medicine<\/span><\/li>\n<li><span class=\"doctorDate\">2012<\/span> <span class=\"doctorDescription\">Yeditepe University Faculty of Medicine<\/span><\/li>\n<\/ul>\n<p><strong>Experience<\/strong><\/p>\n<ul>\n<li><span class=\"doctorDate\">2025<\/span> <span class=\"doctorDescription\">Acibadem Health Group<\/span><\/li>\n<li><span class=\"doctorDate\">2023 \u2013 2025<\/span> <span class=\"doctorDescription\">Kanuni Sultan S\u00fcleyman Training and Research Hospital \/ Medical Oncology Specialist<\/span><\/li>\n<li><span class=\"doctorDate\">2019 \u2013 2020<\/span> <span class=\"doctorDescription\">Haydarpasa Numune Training and Research Hospital \/ Internal Medicine Specialist<\/span><\/li>\n<\/ul>\n<p><strong>Publications<\/strong><\/p>\n<ul>\n<li><strong>A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy.<\/strong><br>\nJ Clin Oncol. 2025 ;43(16_suppl): 1203 3. Goktas Aydin S, Aydin A, Demirel BC, et al.<\/li>\n<li><strong>Predicting osteoporosis in elderly cancer patients using the modified Glasgow prognostic index<\/strong><br>\nCancer Control. 2025;32:10732748251337601. Ustuner M, Goktas Aydin S, Aydin A, et al<\/li>\n<li><strong>Real world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: a Turkish oncology group retrospective study.<\/strong><br>\nMol Clin Oncol. 2025;22(6):51. Ozgun A, Mustafayev FNA, Dogan I, et al<\/li>\n<li><strong>Assessment of health literacy and HPV knowledge among university students: an observational study<\/strong><br>\nMedicine (Baltimore). 2024; 103(35). Senocak Tasci E, Bas D, Kayak S, et al.<\/li>\n<li><strong>Real-world efficacy and safety of f\u0131rst-line nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal esophageal adenocarcinoma: a nationwide observational Turkish Oncology Group (TOG) study.<\/strong><br>\nCancers (Basel). 2024; 16(12):2251. Kutlu Y, Shute DA, Yilmaz F, et al.<\/li>\n<li><strong>Total neoadjuvant therapy versus neoadjuvant chemoradiation for locally advanced rectal cancer: a multi-institutional real-world study.<\/strong><br>\nCancers (Basel). 2024; 16( 18):3213. Senocak Tasci E, Mutlu AU, Saylik O, et al<\/li>\n<li><strong>BEGEV is an effective therapy for heavily pretreated and platinum-resistant relapsed\/refractory Hodgkin\u2019s lymphoma patients: a single-center real-life experience.<\/strong><br>\nIndian J Hematol Blood Transfus. 2024 Uzay A, Tasci ES, Gundogdu Y, et al.<\/li>\n<li><strong>Efficacy of adjuvant capecitabine in residual triple-negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.<\/strong><br>\nExpert Opin Pharmacother. 2024:1-8. Tasci ES, Kutlu Y, \u00d6lmez \u00d6F, et al<\/li>\n<li><strong>Turkish adaptation of QEQ-SH22 quality of sexual life assessment scale in cancer patients \u2013 validity and reliability study<\/strong><br>\nSisli Etfal Hastan Tip Bul. 2024;58(4):468-476. Eri\u015f SB, Celayir OM, Tasci ES, et al.<\/li>\n<li><strong>Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).<\/strong><br>\nTurkish J Med Sci. 2022;52(4): 1022-1032. Erol C, Sakin A, Basoglu T, et al.<\/li>\n<\/ul>\n<\/div>\n","protected":false},"featured_media":17181,"template":"","categories":[16,4,842],"class_list":["post-17180","idel_doctor","type-idel_doctor","status-publish","has-post-thumbnail","hentry","category-atakent-hospital","category-doctors","category-oncology"],"_links":{"self":[{"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/idel_doctor\/17180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/idel_doctor"}],"about":[{"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/types\/idel_doctor"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/media\/17181"}],"wp:attachment":[{"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/media?parent=17180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/categories?post=17180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}